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We report a case of a vaginal infection caused by a
strain of Burkholderia cenocepacia. The strain was isolated
from vaginal swab specimens from a 68-year-old woman
with smoldering myeloma and chronic hepatitis C virus
infection who was hospitalized for abdominal abscess.
Treatment with piperacillin/tazobactam eliminated B. ceno-
cepacia infection and vaginal symptoms. 
M
embers of genus Burkholderia are aerobic,
non–spore-forming, catalase-positive, gram-nega-
tive bacteria; most are oxidase positive (1). This genus
comprises opportunistic pathogens responsible for impor-
tant infections in immunocompromised persons and in
cystic fibrosis (CF) patients (2,3). To date, the genus
Burkholderia comprises more than 30 species, including
the  Burkholderia cepacia complex,  B. mallei, and B.
pseudomallei (2). The B. cepacia complex is a group of
microorganisms composed of at least nine closely related
genomovars (2,3). All genomovars have been shown to
cause infections, and B. cenocepacia and B. multivorans
(genomovars III and II, respectively) are the genomovars
most frequently isolated from CF patients (4–7). 
Nosocomial infections caused by B. cepacia complex
have been reported in non-CF patients, principally associ-
ated with the use of contaminated disinfectants, anaesthet-
ic solutions, and invasive treatments such as urinary and
intravenous catheterization (8). These strains are intrinsi-
cally resistant to most antimicrobial agents and are diffi-
cult to eliminate (8,9). Cases of B. cepacia complex
infections are underestimated because of the complex tax-
onomy of this genus and the poor sensitivity and specifici-
ty of commercial identification systems (10). Recently,
molecular methods, mainly polymerase chain reaction
(PCR)-based, have been developed to circumvent this
issue (10–13).
We report a case of vaginal infection, caused by B.
cenocepacia, in a patient affected by smoldering myeloma,
and chronic hepatitis C virus (HCV) infection. Bacterial
identification at species level was assessed by four com-
bined PCR–based molecular methods. Therapy based on
treatment with piperacillin/tazobactam completely elimi-
nated the infection as well as the vaginal symptoms.
Case Report 
In August 2003, a 68-year-old woman with smoldering
myeloma and chronic HCV infection (the patient had cir-
rhosis since 1994) was admitted to the “Sant’Andrea”
Hospital (2nd Faculty of Medicine, “La Sapienza”
University, Rome, Italy), with a 15-day history of fever,
malaise, asthenia, fatigue, abdominal pain, and swelling of
lower limbs. One week before admission, she had been
treated with ciprofloxacin (500 mg twice a day) without
improvement of any of the clinical symptoms. On admis-
sion (day 1), the patient had a fever (38.4°C) and showed
abundant ascitic fluid and jaundice. Laboratory values
were indicative of macrocytic anemia (erythrocytes, 3.6 x
109/L; hemoglobin, 110 g/L; mean corpuscular volume,
103 fL; hematocrit, 31%; serum iron level, 10.74 µmol/L;
and serum ferritin level, 170 µg/L. Platelet count was 46 x
109/L, and leukocyte count was 14 x 109/L with neu-
trophils (13 x 109/L) and lymphocytes (0.5 x 109/L). The
patient had high values of the erythrocyte sedimentation
rate (ESR) in the first hour (71 mm/h) and C-reactive pro-
tein (CRP) (4.1 mg/L). Increased total serum proteins (8.1
g/dL) and hypoalbuminemia (23 g/L) were also detected.
Six blood samples were taken at 3-hour intervals during
the first day of hospitalization and cultured to detect the
growth of aerobic and anaerobic microorganisms (Bactec
System, Becton Dickinson, Sparks, MD). All blood cul-
tures were negative. Abdominal ecographic and tomo-
graphic scans showed a pseudocystic formation in the
pancreas. The pancreatic formation was drained because
surgical intervention was not appropriate for the patient.
On admission day 2, the patient was transferred to the
Infectious Diseases Unit; there, intensive strong diuretic
therapy was initiated, and a urinary catheter was inserted.
Results of microbiologic analysis of urine and of a liquid
taken from the pseudocystic formation were negative for
common pathogenic bacteria. In spite of these results, the
patient was given intravenous amoxicillin/clavulananate
(1.2 g three times a day) and amikacin (1 g once a day)
(day 3). After 5 days of antimicrobial drug therapy, the
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9 (i.e., after 6 days of antimicrobial drug therapy and 7
days of urinary catheterization), the patient exhibited an
abundant white vaginal discharge with vulvar pain and
burning. Vaginal swabs were streaked on different selec-
tive media. Columbia agar base, supplemented with 5%
(vol/vol) sheep blood, and MacConkey agar plates showed
a monomicrobic culture constituted by catalase-positive
and oxidase-positive gram-negative rods that did not grow
under anaerobic conditions. A presumptive identification
of  B. cepacia was made by using the API20NE
(bioMérieux, Marcy l’Etoile, France), while the Vitek 2.0
identification system (bioMérieux) did not recognize the
isolate as B. cepacia (10). Identification at the species level
was achieved by four different PCR-based combined
molecular methods, namely, DdeI and HaeIII restriction
fragment length polymorphisms (RFLP) of 16S rDNAand
recA gene analysis, recA genomovar-specific PCR, and
recA sequence analysis (11–13). Control strains belonging
to different genomovars of B. cepacia complex were
included in all molecular analyses (14). Bacterial genomic
DNA was extracted by using a commercial kit (Qiagen
genomic-tip, Qiagen Inc., Hilden, Germany) as previously
described (14). The bacterial isolate showed a 16S rRNA
DdeI-RFLP pattern 1 and a recA HaeIII-RFLP pattern H
(data not shown; 14), patterns indicative of B. cenocepacia
(11–14). Genomovar-specific PCR was performed with
primer pairs annealing to internal regions of the recA gene
(12,13). A DNA fragment with a molecular mass of
approximately 800 bp, consistent with the expected 781-bp
B. cenocepacia amplification fragment, was successfully
amplified with the primer pair BCRG3B1/BCRG3B2 (data
not shown) (12,13). To unambiguously identify the bacte-
rial isolate, we sequenced the amplified recA DNA frag-
ment that was subjected to recA HaeIII-RFLP analysis
(13). The recA DNA sequence of the bacterial isolate
(GenBank accession no. AJ786367), subjected to BLAST
analysis (http://www.ncbi.nlm.nih.gov/BLAST), showed
>99% homology with the recA sequence of the B. ceno-
cepacia reference strain LMG 18829 (GenBank accession
no. AF143784). Phylogenetic analysis, based on recA
DNA sequences, indicated that the clinical isolate
belonged to the B. cenocepacia (genomovar III, lineage
IIIB) (Figure) (4,13).
The B. cenocepacia isolate was resistant to penicillin,
mezlocillin, piperacillin, amoxicillin/clavulanate, nitrofu-
rantoin, ciprofloxacin, carbapenems, cephalosporins,
aminoglycosides, and tetracycline and sensitive to
trimethoprim/sulfamethoxazole and piperacillin/tazobac-
tam. When the antimicrobial drug susceptibility profile
was considered, the amoxicillin/clavulanate and amikacin
antibiotic therapy was interrupted, and intravenous
piperacillin/tazobactam combination was administered
(4.5 g, three times a day for 4 weeks). Vaginal swabs were
taken every 3 days during the 4 weeks of the antimicrobial
drug therapy and, afterwards, every 20 days for a total fol-
low-up period of 3 months. After 10 days of the
piperacillin/tazobactam treatment, vaginal symptoms dis-
appeared and cultured vaginal swabs did not show B. ceno-
cepacia. After the piperacillin/tazobactam treatment
ended, the patient did not exhibit any signs of vaginal
infection. 
Conclusions
We think this is the first description of a vaginal infec-
tion caused by B. cenocepacia. The patient’s immunode-
pression from smoldering myeloma and chronic HCV
likely favored vaginal colonization by B. cenocepacia.
Urinary catheterization might have favored vaginal colo-
nization by B. cenocepacia, even if we did not isolate B.
cenocepacia  from catheters, disinfectants, and selected
hospital environmental samples analyzed from October
2003 to date February 2004 (15). Moreover, the antimicro-
bial agents, ciprofloxacin, and amoxicillin/clavulanate and
amikacin, administered to the patient before and during
hospitalization, might also have altered the patient’s vagi-
nal flora. Piperacillin/tazobactam eliminated vaginal
symptoms and B. cenocepacia from the vaginal mucosa,
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Figure. The consensus phylogenetic tree of recA DNA sequences
of Burkholderia cepacia complex strains, representative of each
genomovar, and of the B. cenocepacia isolate (GenBank acces-
sion no. AJ786367) was constructed with the PHYLIP package
(version 3.6) (http://evolution.genetics.washington.edu/phylip.
html). Only recA DNA sequences of reference B. cenocepacia
strains (genomovar III, lineage IIIB) are included in the tree (4,13).
Alignments were performed with the Clustal W program. Genetic
distance is indicated on the scalethus indicating that the detected isolate was indeed respon-
sible for the infection.
Microorganisms belonging to the B. cepacia complex
are difficult to identify by conventional biochemical tests
and commercial systems (8). This case report highlights
the importance of the use of molecular techniques to
quickly and accurately identify members of the B. cepacia
complex (10,13). The ability of B. cenocepacia to cause
vaginal infections is unusual. Further studies are needed to
clarify whether specific virulence factors are carried and
expressed by the B. cenocepacia clinical isolate, confer-
ring to this strain the specific ability to colonize and mul-
tiply within the vaginal mucosa.
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